JP2014502955A - 抗体 - Google Patents

抗体 Download PDF

Info

Publication number
JP2014502955A
JP2014502955A JP2013534894A JP2013534894A JP2014502955A JP 2014502955 A JP2014502955 A JP 2014502955A JP 2013534894 A JP2013534894 A JP 2013534894A JP 2013534894 A JP2013534894 A JP 2013534894A JP 2014502955 A JP2014502955 A JP 2014502955A
Authority
JP
Japan
Prior art keywords
antibody
cdh17
antibodies
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013534894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502955A5 (enExample
Inventor
アレクアンデル テルレトト ジョナトハン
Original Assignee
オックスフォード ビオトヘラペウトイクス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード ビオトヘラペウトイクス エルティーディー． filed Critical オックスフォード ビオトヘラペウトイクス エルティーディー．
Publication of JP2014502955A publication Critical patent/JP2014502955A/ja
Publication of JP2014502955A5 publication Critical patent/JP2014502955A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
JP2013534894A 2010-10-20 2011-10-19 抗体 Pending JP2014502955A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40509010P 2010-10-20 2010-10-20
US61/405,090 2010-10-20
PCT/US2011/001787 WO2012054084A2 (en) 2010-10-20 2011-10-19 Antibodies

Publications (2)

Publication Number Publication Date
JP2014502955A true JP2014502955A (ja) 2014-02-06
JP2014502955A5 JP2014502955A5 (enExample) 2014-12-11

Family

ID=45975790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534894A Pending JP2014502955A (ja) 2010-10-20 2011-10-19 抗体

Country Status (15)

Country Link
US (2) US20130259878A1 (enExample)
EP (1) EP2629796A4 (enExample)
JP (1) JP2014502955A (enExample)
KR (1) KR20130138802A (enExample)
CN (1) CN103534268B (enExample)
AU (1) AU2011318574B2 (enExample)
BR (1) BR112013009551A2 (enExample)
CA (1) CA2815041A1 (enExample)
EA (1) EA201300470A1 (enExample)
IL (1) IL225571A0 (enExample)
MX (1) MX2013004476A (enExample)
NZ (1) NZ610091A (enExample)
SG (1) SG189835A1 (enExample)
WO (1) WO2012054084A2 (enExample)
ZA (1) ZA201302459B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518721A (ja) * 2016-01-09 2019-07-04 アーベル リミテッドＡｒｂｅｌｅ Ｌｉｍｉｔｅｄ がん処置のためのカドヘリン−１７特異的抗体及び細胞傷害性細胞
JP2020501586A (ja) * 2016-12-22 2020-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
JP2024537266A (ja) * 2021-10-08 2024-10-10 ティベリアス テクノロジー （エイチケー） リミテッド Ｃｄｈ１７を検出するためのｔｉｂｔｅｃｈの方法及び組成物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
RU2648141C2 (ru) * 2012-09-19 2018-03-22 Эббви Биотерапьютикс Инк. Способы идентификации антител с пониженной иммуногенностью
SG10201800265UA (en) * 2016-06-17 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
US12410234B2 (en) 2018-04-26 2025-09-09 The Trustees Of The University Of Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены
US20210116456A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Compositions and methods for diagnosis and treatment of cancer
WO2019222428A1 (en) * 2018-05-16 2019-11-21 Arbele Limited Composition of bispecific antibodies and method of use thereof
US20250270314A1 (en) * 2021-08-02 2025-08-28 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car
CN120917040A (zh) * 2023-01-31 2025-11-07 毕格哈特生物科学公司 抗cdh17抗体及其用途
EP4669672A1 (en) * 2023-02-23 2025-12-31 Hansoh Bio LLC ANTIBODIES, ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE
JP2026518758A (ja) * 2023-05-24 2026-06-09 マルティテュード・セラピューティクス・インコーポレイテッド 抗体及びその抗体薬物複合体
KR20260082360A (ko) * 2023-09-22 2026-06-04 레푸 바이오파마 컴퍼니 리미티드 항-cdh17 항체 및 이의 용도
CN120230211A (zh) * 2023-12-29 2025-07-01 广东菲鹏制药股份有限公司 抗cdh17抗体或其抗原结合片段及其应用
TW202547885A (zh) * 2024-04-30 2025-12-16 中國商蘇州宜聯生物醫藥有限公司 抗體、抗體藥物偶聯物及其用途
TW202613168A (zh) * 2024-05-20 2026-04-01 大陸商杭州中美華東製藥有限公司 抗cdh17抗體、其抗體藥物偶聯物及其用途
WO2025242100A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体及其用途
TW202613172A (zh) * 2024-05-31 2026-04-01 大陸商江蘇先聲生物製藥有限公司 抗cdh17抗體、綴合物及其應用
WO2025252211A1 (zh) * 2024-06-07 2025-12-11 映恩生物制药（苏州）有限公司 抗人cdh17抗体
WO2026067602A1 (zh) * 2024-09-26 2026-04-02 上海翰森生物医药科技有限公司 一种含抗体药物偶联物的药物组合物及其用途
WO2026090578A1 (en) * 2024-10-25 2026-04-30 Antharis Therapeutics Inc. Cdh17-binding antibodies and methods of use thereof
CN120554510B (zh) * 2025-05-29 2026-05-12 吉林大学 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
JP2003512019A (ja) * 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
WO2009116670A1 (ja) * 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
WO2010040277A1 (en) * 2008-10-09 2010-04-15 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010095461A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
WO2010117057A1 (ja) * 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
JP2012523848A (ja) * 2009-04-20 2012-10-11 オックスフォード ビオトヘラペウトイクス エルティーディー． カドヘリン−１７に特異的な抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US7615529B2 (en) * 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
US8535677B2 (en) * 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512019A (ja) * 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
WO2009116670A1 (ja) * 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
WO2010040277A1 (en) * 2008-10-09 2010-04-15 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010095461A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
WO2010117057A1 (ja) * 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
JP2012523848A (ja) * 2009-04-20 2012-10-11 オックスフォード ビオトヘラペウトイクス エルティーディー． カドヘリン−１７に特異的な抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PROC. NATL. ACAD. SCI, USA, vol. 86, JPN6015046020, 1989, pages 10029 - 10033, ISSN: 0003196722 *
PROC. NATL. ACAD. SCI, USA, vol. 89, JPN6015046017, 1992, pages 4285 - 4289, ISSN: 0003196723 *
PROTEIN ENGINEERING, vol. 11, no. 4, JPN6015046018, 1998, pages 321 - 328, ISSN: 0003196724 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518721A (ja) * 2016-01-09 2019-07-04 アーベル リミテッドＡｒｂｅｌｅ Ｌｉｍｉｔｅｄ がん処置のためのカドヘリン−１７特異的抗体及び細胞傷害性細胞
JP2022036939A (ja) * 2016-01-09 2022-03-08 アーベル リミテッド がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞
JP7275232B2 (ja) 2016-01-09 2023-05-17 アーベル リミテッド がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞
JP2023109790A (ja) * 2016-01-09 2023-08-08 アーベル リミテッド がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞
JP7482287B2 (ja) 2016-01-09 2024-05-13 アーベル リミテッド がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞
JP2020501586A (ja) * 2016-12-22 2020-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
JP7196076B2 (ja) 2016-12-22 2022-12-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
JP2024537266A (ja) * 2021-10-08 2024-10-10 ティベリアス テクノロジー （エイチケー） リミテッド Ｃｄｈ１７を検出するためのｔｉｂｔｅｃｈの方法及び組成物

Also Published As

Publication number Publication date
IL225571A0 (en) 2013-06-27
EP2629796A4 (en) 2015-01-28
KR20130138802A (ko) 2013-12-19
EP2629796A2 (en) 2013-08-28
NZ610091A (en) 2015-02-27
CA2815041A1 (en) 2012-04-26
CN103534268A (zh) 2014-01-22
AU2011318574B2 (en) 2016-03-03
US20150093392A1 (en) 2015-04-02
AU2011318574A1 (en) 2013-05-02
WO2012054084A2 (en) 2012-04-26
EA201300470A1 (ru) 2014-05-30
US20130259878A1 (en) 2013-10-03
SG189835A1 (en) 2013-06-28
ZA201302459B (en) 2014-01-29
BR112013009551A2 (pt) 2016-07-12
MX2013004476A (es) 2013-06-28
WO2012054084A3 (en) 2013-10-17
CN103534268B (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
JP6141638B2 (ja) カドヘリン−１７に特異的な抗体
CN103534268B (zh) 抗体
JP6247209B2 (ja) Ａｄｐリボシルシクラーゼ２に対する抗体
CN111971091A (zh) 预防或治疗骨髓发育不良综合征的抗bst1抗体
HK1164331B (en) Antibodies specific to cadherin-17
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
EA052228B1 (ru) Антитела против cd38 для лечения множественной миеломы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228